C3L-02163
— · cohortSQ2
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortSQ2
- subtype
- cohortSQ2
- age_years
- 57.54962355
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- WNT_BETA_CATENIN_SIGNALING+0.420
- KRAS_SIGNALING_DN+0.340
- APICAL_SURFACE+0.220
- MYC_TARGETS_V2+0.190
- HYPOXIA+0.150
- P53_PATHWAY+0.110
- MYOGENESIS+0.100
- SPERMATOGENESIS+0.100
- ESTROGEN_RESPONSE_LATE+0.080
- HEDGEHOG_SIGNALING+0.070
Top 10 suppressed
- IL6_JAK_STAT3_SIGNALING-0.510
- INTERFERON_ALPHA_RESPONSE-0.510
- INTERFERON_GAMMA_RESPONSE-0.510
- ALLOGRAFT_REJECTION-0.490
- COMPLEMENT-0.440
- ANDROGEN_RESPONSE-0.430
- INFLAMMATORY_RESPONSE-0.400
- KRAS_SIGNALING_UP-0.390
- TNFA_SIGNALING_VIA_NFKB-0.370
- PROTEIN_SECRETION-0.330
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-NC-A5HF-01A-11R-A26W-07 | — | cohortSQ1 | 0.868 |
| 2 | c3b46d4b-4d9f-4d2d-bbca-c0dbd6901e56 | — | — | 0.822 |
| 3 | SRR12202412 | — | — | 0.815 |
| 4 | TCGA-56-A4BX-01A-11R-A24H-07 | — | cohortSQ2 | 0.813 |
| 5 | TCGA-85-7696-01A-11R-2125-07 | — | cohortSQ2 | 0.811 |
| 6 | SRR1379562 | GTEX | — | 0.807 |
| 7 | 8683d8f5-bba5-40a1-a460-ad6183d2302b | — | — | 0.806 |
| 8 | 6c9ce1b6-eef5-4c2f-b031-d973e0821a48 | — | — | 0.804 |
| 9 | SRR1470175 | GTEX | — | 0.800 |
| 10 | TCGA-85-A5B5-01A-21R-A26W-07 | — | cohortSQ2 | 0.799 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 14 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| WNT_BETA_CATENIN_SIGNALING | 0.420 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.340 | Remibrutinib | — uncovered |
| APICAL_SURFACE | 0.220 | Temsirolimus | — uncovered |
| MYC_TARGETS_V2 | 0.190 | Idelalisib | — uncovered |
| HYPOXIA | 0.150 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.110 | Idelalisib | — uncovered |
| MYOGENESIS | 0.100 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.100 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.080 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.070 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.060 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.050 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.050 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.010 | Inavolisib | — uncovered |